Kin­nate Bio­phar­ma touts ear­ly ef­fi­ca­cy in pan-RAF pro­gram: #AACR23

OR­LAN­DO — Af­ter suf­fer­ing two de­lays last year, Kin­nate Bio­phar­ma is of­fer­ing an ear­ly-stage look at its monother­a­py pan-RAF in­hibitor, while de­pri­or­i­tiz­ing a pre­clin­i­cal pro­gram to hone in on more ad­vanced pro­grams.

Cur­rent­ly avail­able RAF in­hibitors such as No­var­tis’ Tafin­lar, Pfiz­er’s Braftovi and Roche’s Zelb­o­raf tar­get class I BRAF ki­nase mu­ta­tions. Kin­nate’s exarafenib, on the oth­er hand, was de­signed to al­so tar­get class II and III mu­ta­tions, which con­sti­tute rough­ly 55% of onco­genic BRAF mu­ta­tions, ac­cord­ing to the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER